CA2676583C - Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid - Google Patents
Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid Download PDFInfo
- Publication number
- CA2676583C CA2676583C CA2676583A CA2676583A CA2676583C CA 2676583 C CA2676583 C CA 2676583C CA 2676583 A CA2676583 A CA 2676583A CA 2676583 A CA2676583 A CA 2676583A CA 2676583 C CA2676583 C CA 2676583C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- red yeast
- yeast rice
- omega
- epa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents.
Description
Composition Comprising Red Yeast Rice and an Omega-3 Polyunsaturated Fatty Acid BACKGROUND OF THE INVENTION
Field of the Invention The invention relates to compositions and methods of use of supplements and medicaments, which combine Red Yeast Rice extract, having hydroxymethylglutaryl-CoA
(HMG-CoA) reductase inhibitor activity, with omega -3 fatty acid components derived from fish oils in a combined unit dose.
Description of the Prior Art =
The statins (which are members of a group of BMG-CoA reductase inhibitors) are a group of hypolipidemic agents, used as pharmaceutical agents to lower cholesterol levels in people with or at risk for cardiovascular disease. They lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting enzyme of the mevalonate pathway of cholesterol synthesis. Inhibition of this enzyme in the liver stimulates low-density lipoprotein (LDL) receptors, resulting in an increased clearance of LDL, so-called "bad cholesterol", from the bloodstream and a decrease in blood cholesterol levels.
Statins, are potent cholesterol-lowering agents, and have been reported to lower LDL
cholesterol by 30-50%.' Statins are classified as either synthetic or fermentation derived.
Lovastatin was isolated from a strain of Aspergillus terreus and it was the first statin approved by the FDA as a drug (August 1987). Lovastatin is a water insoluble, white crystalline solid. The aqueous insolubility of lovastatin leads to inadequate dissolution in gastrointestinal fluids and, hence, poor absorption, distribution, and targeted organ delivery. Solubility of lovastatin is enhanced by reaction with fl-cyclodextrin an oligosaccharide which improves the solubility of lovastatin. The improvement of aqueous solubility in such a case is a valuable goal to improve therapeutic efficacy.
Lovastatin can also produce slight to moderate increases in high density lipoproteins (HDL) (10-20%), 'Jones P, Kafonek S. Laurora I, eta] !Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin: lovastatin, and fluvastatin in patients with hypercholesterolemia. (the CURVES study)". Am J Cardiol 1998; 81-(5): 582-7.
and slight decreases in triglycerides (5-10%). The usual daily dose of lovastatin is 20-80 mg/day. The statin drugs include lovastatin, pravastatin, fluvastatin, atorvastatin, simvastatin, rosuvastatin, and cerivastatin.
Compounds similar to lovastatin have also been found as an ingredient in a natural fermentation product known as Red Yeast Rice, which are also members of the HMG-CoA inhibitors. A monograph published in Alternative Medicine Review (Volume 9, Number 2, 2004) reports that the HMG-CoA reductase inhibitor activity in Red Yeast Rice comes from a naturally occurring family of nine compounds called monacolins, each of which has HMG-CoA reductase inhibitor activity. Additional active ingredients in Red Yeast Rice include sterols (beta-sitosterol, campesterol, sigmasterol, and sapogenin), isoflavones, and monounsaturated fatty acids'. One of the monacolins, monacolin K, is said to be the lactone form of the statin drug lovastatin, which is converted to the active acid form in vivo by the liver. Red yeast rice is a common foodstuff in Asian countries where the average daily intake is 14-55 grams. The nutritional supplement derived from Red Yeast Rice is Red Yeast Rice extract, which is obtained by drying the fermented product of rice on which the yeast Alonascu s puipureus has been grown and extracting the dried product with a solvent, usually aqueous ethanol or water. The Red Yeast Rice extract contains about 0.2% monacolin K and about 0.5% total monacolins.
U.S. 6,046,022 to Zhang, et al (Peking University), discloses some methods of making high lovastatin (monacolin K) red yeast rice and using red yeast rice and red yeast rice extract. U.S. 6,046,022.
U.S. 6,541,005, 6,436,406, 6,495,173, 6,544,525, 6,576,242, 6,541,006 and 6,410,521 all issued to Baswell disclose methods of using red yeast rice.
Field of the Invention The invention relates to compositions and methods of use of supplements and medicaments, which combine Red Yeast Rice extract, having hydroxymethylglutaryl-CoA
(HMG-CoA) reductase inhibitor activity, with omega -3 fatty acid components derived from fish oils in a combined unit dose.
Description of the Prior Art =
The statins (which are members of a group of BMG-CoA reductase inhibitors) are a group of hypolipidemic agents, used as pharmaceutical agents to lower cholesterol levels in people with or at risk for cardiovascular disease. They lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting enzyme of the mevalonate pathway of cholesterol synthesis. Inhibition of this enzyme in the liver stimulates low-density lipoprotein (LDL) receptors, resulting in an increased clearance of LDL, so-called "bad cholesterol", from the bloodstream and a decrease in blood cholesterol levels.
Statins, are potent cholesterol-lowering agents, and have been reported to lower LDL
cholesterol by 30-50%.' Statins are classified as either synthetic or fermentation derived.
Lovastatin was isolated from a strain of Aspergillus terreus and it was the first statin approved by the FDA as a drug (August 1987). Lovastatin is a water insoluble, white crystalline solid. The aqueous insolubility of lovastatin leads to inadequate dissolution in gastrointestinal fluids and, hence, poor absorption, distribution, and targeted organ delivery. Solubility of lovastatin is enhanced by reaction with fl-cyclodextrin an oligosaccharide which improves the solubility of lovastatin. The improvement of aqueous solubility in such a case is a valuable goal to improve therapeutic efficacy.
Lovastatin can also produce slight to moderate increases in high density lipoproteins (HDL) (10-20%), 'Jones P, Kafonek S. Laurora I, eta] !Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin: lovastatin, and fluvastatin in patients with hypercholesterolemia. (the CURVES study)". Am J Cardiol 1998; 81-(5): 582-7.
and slight decreases in triglycerides (5-10%). The usual daily dose of lovastatin is 20-80 mg/day. The statin drugs include lovastatin, pravastatin, fluvastatin, atorvastatin, simvastatin, rosuvastatin, and cerivastatin.
Compounds similar to lovastatin have also been found as an ingredient in a natural fermentation product known as Red Yeast Rice, which are also members of the HMG-CoA inhibitors. A monograph published in Alternative Medicine Review (Volume 9, Number 2, 2004) reports that the HMG-CoA reductase inhibitor activity in Red Yeast Rice comes from a naturally occurring family of nine compounds called monacolins, each of which has HMG-CoA reductase inhibitor activity. Additional active ingredients in Red Yeast Rice include sterols (beta-sitosterol, campesterol, sigmasterol, and sapogenin), isoflavones, and monounsaturated fatty acids'. One of the monacolins, monacolin K, is said to be the lactone form of the statin drug lovastatin, which is converted to the active acid form in vivo by the liver. Red yeast rice is a common foodstuff in Asian countries where the average daily intake is 14-55 grams. The nutritional supplement derived from Red Yeast Rice is Red Yeast Rice extract, which is obtained by drying the fermented product of rice on which the yeast Alonascu s puipureus has been grown and extracting the dried product with a solvent, usually aqueous ethanol or water. The Red Yeast Rice extract contains about 0.2% monacolin K and about 0.5% total monacolins.
U.S. 6,046,022 to Zhang, et al (Peking University), discloses some methods of making high lovastatin (monacolin K) red yeast rice and using red yeast rice and red yeast rice extract. U.S. 6,046,022.
U.S. 6,541,005, 6,436,406, 6,495,173, 6,544,525, 6,576,242, 6,541,006 and 6,410,521 all issued to Baswell disclose methods of using red yeast rice.
2 Heber a et al,.,Cholesterol Lowering effects of Proprietary Chinese red yeast rice dietary supplement.
Am J Clin Nutr 199969:231-236.
U.S. Application 20060211763 discloses a statin drug dissolved in [a]solvent system comprising natural or synthetic omega-3 fatty acids and U.S. Application discloses novel omega-3 oil solutions of one or more statins.
Omega-3 fatty acids are primarily derived from fish oils and are known to reduce serum triglycerides3 and adverse coronary events. The principal active ingredients in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which were given at a combined dose of 4 g/day for seven months to hypertriglyceridemic patients resulting in a reduction of 47% in triglycerides4.
The effects of statin drugs and omega-3 are cumulative. When 59 patients who were already receiving 10-40 mg daily of the statin simvastin were given 2 grams twice daily of EPA+DHA, there was a further sustained significant decrease of 20-30% in triglycrides.5 Omega-3s are also well known to those skilled in the art to reduce inflammation, decrease arrhythmias, decrease risk of sudden cardiac death and cardiac arrest.
Considering the similarities and advantages of Red Yeast Rice compared to the statin drugs, and the complementary nature of statin drugs and Omega-3 fatty acids, there is a need for a combined Red Yeast Rice Extract with Omega-3 fatty acids in a combined unit dose form SUMMARY OF THE INVENTION
The invention comprises red yeast rice extract dispersed in omega-3 fatty acids. The red yeast rice extract preferably comprises, at least one and preferably more than one
Am J Clin Nutr 199969:231-236.
U.S. Application 20060211763 discloses a statin drug dissolved in [a]solvent system comprising natural or synthetic omega-3 fatty acids and U.S. Application discloses novel omega-3 oil solutions of one or more statins.
Omega-3 fatty acids are primarily derived from fish oils and are known to reduce serum triglycerides3 and adverse coronary events. The principal active ingredients in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which were given at a combined dose of 4 g/day for seven months to hypertriglyceridemic patients resulting in a reduction of 47% in triglycerides4.
The effects of statin drugs and omega-3 are cumulative. When 59 patients who were already receiving 10-40 mg daily of the statin simvastin were given 2 grams twice daily of EPA+DHA, there was a further sustained significant decrease of 20-30% in triglycrides.5 Omega-3s are also well known to those skilled in the art to reduce inflammation, decrease arrhythmias, decrease risk of sudden cardiac death and cardiac arrest.
Considering the similarities and advantages of Red Yeast Rice compared to the statin drugs, and the complementary nature of statin drugs and Omega-3 fatty acids, there is a need for a combined Red Yeast Rice Extract with Omega-3 fatty acids in a combined unit dose form SUMMARY OF THE INVENTION
The invention comprises red yeast rice extract dispersed in omega-3 fatty acids. The red yeast rice extract preferably comprises, at least one and preferably more than one
3 Abe Y. El-Masri B. et al, Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arteriosler Thromb l'asc Biology 1998:18:723-731.
4 Ridker. Paul. Effects of n-3 Fatty Acid Therapy on Lipids and sCAMs -Inflammatory Markers, Pharmacotherapy and Clinical Trials. Lipids Online.org. posted: October 3.
2001. reviewed October 4.
2001.
2001. reviewed October 4.
2001.
5 Durington P. Bhatnager. et al. An omega-3 polyunsaturated fatty acid concentration administered for one year decreased triglycerides in simvastin treated patients with CHD. Heart 2001:85(5) 544-548.
monacolin compounds, including monacolin K preferably at least one other monacolin and more preferably all of the other nine monacolins. The red yeast rice extract preferably contains about 0.2% monacolin K and 0.5% of total monacolins. The red yeast rice is the extract of fermenting -white rice, preferably non-glutinous white rice, with Monascus purpureus strain of yeast, culturing said Monascus purpureus strain in a culture medium comprising rice at a temperature of about 15 C to about 35 C for a period of about 2 to about 20 days to provide a crude fermentation product containing red rice;
drying said crude fermentation product to obtain red yeast rice, and extracting said red yeast rice with a solvent to provide an extract; and- drying said extract to remove the solvent and produce red yeast rice extract. The solvent is preferably either aqueous ethanol or water. Other culture media may be added to the rice. For example, sugar, an additional carbon source chosen from the group consisting of glycerine, malt, and potato juice; thick beef juice, and defoamer. The red yeast rice extract preferably contains about 0.2% monacolin K and 0.5% of total monacolins. Red Yeast Rice extracts are readily available in commerce in the United States and may be purchased already prepared. The preferred daily dose of red yeast rice extract is 1.2 to 2.4 grams per day, which were the dosages used in human clinical trials.
It is preferred to use a high quality source of omega-3, which is rich in Omega-3 Oils, preferably at least 70% Omega-3 Oils, and also rich in EPA and DHA.
Preferably, at least-75% of the Omega Oils are EPA+DHA, and more preferably 85% or more are EPA+DHA. The daily dose of Omega-3 oils is 1 ¨4 grams of Omega-3. One possible source is a balanced Omega-3 formula such as Nordic Naturals, Inc. ProOmegk which is 70% Omega-3 oils of which 50.8% is EPA, 35.1% is DHA and 14.1% is other Omega-3.7 Another preferred omega-3 source is Pro-EPA, which comprises 69.1% EPA, 16.3%
DHA, and 14.6% other omega-3. Still another preferred source is Nordic Naturals Pro-EFA xtra which comprises 56.9% EPA, 14.7% DHA, 17.2% GLA, and 11.2% other Omega-3. The Pro-EFA xtra formula adds an Omega-6, GLA, and makes a powerful anti-inflammatory mixture.
The Red Yeast Rice extract is water soluble and is not soluble in the Omega-3 Oil. A
dispersant is preferably used to keep the Red Yeast Rice extract in suspension. One preferred dispersant is 70% silica bamboo with Lysine made from Sunflower oil. A
suitable mixture is to vigorously mix 24 weights of Red Yeast Rice Extract with 36 weights of Fish Oil, 1.2 weights of Bamboo (2%), and 1.8 weights of Lysine (3%). The mixture may then diluted to the desired omega oil to red yeast rice extract ratio. The omega-3/red yeast rice extract is then preferably encapsulated in soft gelatin capsules for dispensing.
Preferably the capsules are of such a size that an integral number of capsules comprise a daily dosage of the mixture.
A dosage of the mixture further preferably includes antioxidants such as Rosemary, vitamin E, astaxanthine, carnitine, ascorbyl palmitate, tocopherols or other antioxidants known in the art for stabilizing fish oil.
One embodiment of the present invention provides a composition comprising (1) an omega-3 polyunsaturated fatty acid and (2) Red Yeast Rice, wherein component (1) is a mixture comprising at least 70 wt% of a combination of (A) eicosapentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA), wherein the weight ratio of A:B is 3:1 to 4:1, and wherein the Red Yeast Rice comprises at least 0.1 wt% monacolin K.
It is a further feature of the invention to provide a medicament comprising a combined dispersion of Red Yeast Rice Extract in high quality Omega-3 Fatty Acids in unit dose form to make available a medicament for reducing blood lipids and preventing harmful coronary events.
BRIEF DESCRIPTION OF THE DRAWINGS
There are no drawings with this application, containing only composition and process claims.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Comparison between Red Yeast Rice Extract and Lovastatin Red Yeast Rice Extract contains monacolin K, the lactone form of the statin drug Mevacor (lovastatin). Red Yeast Rice extract has been tested in clinical trials at daily dosages of 1.2g and 2.4g. The monacolin K content of the Red Yeast Rice Extract used in the clinical trials was 0.20% of the Red Yeast Rice extract. The monacolin K dose was therefore 2.4 to 4.8 mg/day. At 2.4 mg/day of monacolin K, the total cholesterol, LDL
cholesterol, and triglycerides dropped by 23%, 31%, and 34% respectively. At 4.8 mg/day, the reduction was 17%, 23%, and 16% respectively.6 Lovastatin has been shown to have a cholesterol lowering effect in doses ranging from 10 to 80 mg/day7. A study was performed to show the effectiveness of low-dose lovastatin in lowering serum cholesterol 5. Fifty-six patients were given 20 mg/day of lovastatin for 24 weeks. Total cholesterol fell by 26% and triglycerides fell by 12%.
Mevacor (lovastin) in its package insert reported extensive clinical trials at dosages of 1.0 10, 20, and 40 mg/day. Total cholesterol was reduced in the range from 16-24%, LDL
was reduced by 21-32%, and triglycerides were reduced by 10 to 6% (higher reduction observed at lower dosage).
It should be noted that Red Yeast Rice at a dosage of 2.4 mg/day of monacolin K
produced better lipid reducing results than Mevacor at 10 ¨ 40 mg/day. It is therefore unlikely that the lipid lowering effects with Red Yeast Rice result from the monacolin K
content alone of Red Yeast Rice, but are probably attributable in whole or in part to the other 8 monacolins and sterols (beta-sitosterol, campesterol, sigmasterol, and sapogenin), isoflavones, and monounsaturated fatty acids8. This is a particular advantage since the lower dosage of lovastatin type HMG-CoA reductase inhibitor contributes to reduced side effects as well.
How to make the invention Materials- Red Yeast Rice Extract Red Yeast Rice extract can be purchased as a nutritional supplement in the United States.
Preferred sources include DRACO Natural Products (539 Parrott St., San Jose, CA
monacolin compounds, including monacolin K preferably at least one other monacolin and more preferably all of the other nine monacolins. The red yeast rice extract preferably contains about 0.2% monacolin K and 0.5% of total monacolins. The red yeast rice is the extract of fermenting -white rice, preferably non-glutinous white rice, with Monascus purpureus strain of yeast, culturing said Monascus purpureus strain in a culture medium comprising rice at a temperature of about 15 C to about 35 C for a period of about 2 to about 20 days to provide a crude fermentation product containing red rice;
drying said crude fermentation product to obtain red yeast rice, and extracting said red yeast rice with a solvent to provide an extract; and- drying said extract to remove the solvent and produce red yeast rice extract. The solvent is preferably either aqueous ethanol or water. Other culture media may be added to the rice. For example, sugar, an additional carbon source chosen from the group consisting of glycerine, malt, and potato juice; thick beef juice, and defoamer. The red yeast rice extract preferably contains about 0.2% monacolin K and 0.5% of total monacolins. Red Yeast Rice extracts are readily available in commerce in the United States and may be purchased already prepared. The preferred daily dose of red yeast rice extract is 1.2 to 2.4 grams per day, which were the dosages used in human clinical trials.
It is preferred to use a high quality source of omega-3, which is rich in Omega-3 Oils, preferably at least 70% Omega-3 Oils, and also rich in EPA and DHA.
Preferably, at least-75% of the Omega Oils are EPA+DHA, and more preferably 85% or more are EPA+DHA. The daily dose of Omega-3 oils is 1 ¨4 grams of Omega-3. One possible source is a balanced Omega-3 formula such as Nordic Naturals, Inc. ProOmegk which is 70% Omega-3 oils of which 50.8% is EPA, 35.1% is DHA and 14.1% is other Omega-3.7 Another preferred omega-3 source is Pro-EPA, which comprises 69.1% EPA, 16.3%
DHA, and 14.6% other omega-3. Still another preferred source is Nordic Naturals Pro-EFA xtra which comprises 56.9% EPA, 14.7% DHA, 17.2% GLA, and 11.2% other Omega-3. The Pro-EFA xtra formula adds an Omega-6, GLA, and makes a powerful anti-inflammatory mixture.
The Red Yeast Rice extract is water soluble and is not soluble in the Omega-3 Oil. A
dispersant is preferably used to keep the Red Yeast Rice extract in suspension. One preferred dispersant is 70% silica bamboo with Lysine made from Sunflower oil. A
suitable mixture is to vigorously mix 24 weights of Red Yeast Rice Extract with 36 weights of Fish Oil, 1.2 weights of Bamboo (2%), and 1.8 weights of Lysine (3%). The mixture may then diluted to the desired omega oil to red yeast rice extract ratio. The omega-3/red yeast rice extract is then preferably encapsulated in soft gelatin capsules for dispensing.
Preferably the capsules are of such a size that an integral number of capsules comprise a daily dosage of the mixture.
A dosage of the mixture further preferably includes antioxidants such as Rosemary, vitamin E, astaxanthine, carnitine, ascorbyl palmitate, tocopherols or other antioxidants known in the art for stabilizing fish oil.
One embodiment of the present invention provides a composition comprising (1) an omega-3 polyunsaturated fatty acid and (2) Red Yeast Rice, wherein component (1) is a mixture comprising at least 70 wt% of a combination of (A) eicosapentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA), wherein the weight ratio of A:B is 3:1 to 4:1, and wherein the Red Yeast Rice comprises at least 0.1 wt% monacolin K.
It is a further feature of the invention to provide a medicament comprising a combined dispersion of Red Yeast Rice Extract in high quality Omega-3 Fatty Acids in unit dose form to make available a medicament for reducing blood lipids and preventing harmful coronary events.
BRIEF DESCRIPTION OF THE DRAWINGS
There are no drawings with this application, containing only composition and process claims.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Comparison between Red Yeast Rice Extract and Lovastatin Red Yeast Rice Extract contains monacolin K, the lactone form of the statin drug Mevacor (lovastatin). Red Yeast Rice extract has been tested in clinical trials at daily dosages of 1.2g and 2.4g. The monacolin K content of the Red Yeast Rice Extract used in the clinical trials was 0.20% of the Red Yeast Rice extract. The monacolin K dose was therefore 2.4 to 4.8 mg/day. At 2.4 mg/day of monacolin K, the total cholesterol, LDL
cholesterol, and triglycerides dropped by 23%, 31%, and 34% respectively. At 4.8 mg/day, the reduction was 17%, 23%, and 16% respectively.6 Lovastatin has been shown to have a cholesterol lowering effect in doses ranging from 10 to 80 mg/day7. A study was performed to show the effectiveness of low-dose lovastatin in lowering serum cholesterol 5. Fifty-six patients were given 20 mg/day of lovastatin for 24 weeks. Total cholesterol fell by 26% and triglycerides fell by 12%.
Mevacor (lovastin) in its package insert reported extensive clinical trials at dosages of 1.0 10, 20, and 40 mg/day. Total cholesterol was reduced in the range from 16-24%, LDL
was reduced by 21-32%, and triglycerides were reduced by 10 to 6% (higher reduction observed at lower dosage).
It should be noted that Red Yeast Rice at a dosage of 2.4 mg/day of monacolin K
produced better lipid reducing results than Mevacor at 10 ¨ 40 mg/day. It is therefore unlikely that the lipid lowering effects with Red Yeast Rice result from the monacolin K
content alone of Red Yeast Rice, but are probably attributable in whole or in part to the other 8 monacolins and sterols (beta-sitosterol, campesterol, sigmasterol, and sapogenin), isoflavones, and monounsaturated fatty acids8. This is a particular advantage since the lower dosage of lovastatin type HMG-CoA reductase inhibitor contributes to reduced side effects as well.
How to make the invention Materials- Red Yeast Rice Extract Red Yeast Rice extract can be purchased as a nutritional supplement in the United States.
Preferred sources include DRACO Natural Products (539 Parrott St., San Jose, CA
6 Monograph by Thorne Research Inc., Alternative Medicine Review, Volume 9, Number 2. 2004.
- Bates. M. et al. Effectiveness of low dosage lovastatin in lowering serum cholesterol. Experience with 56 patients,õ Archives of Internal Medicine 1990:150(9) 8 Heber D. et al,_ Cholesterol Lowering effects of Proprietary Chinese red yeast rice dietary supplement, Am J Clin NuM 1999.69:231-236.
95112) Red Yeast Rice Extract 10:1, and the Thorne Research product, Choleast.
Purchased Red Yeast Rice preferably should contain 0.2% or more of Monacolin K
and 0.5% or more of Total Monacolins. We prefer to purchase the extract rather than manufacture it.
Red Yeast Rice Extract can also be manufactured directly from the yeast Monascus purpureus. The red yeast rice is the extract of fermenting- white rice, preferably non-glutinous white rice, with a Monascus purpureus strain of yeast, culturing said Monascus purpureus strain in a culture medium comprising rice at a temperature of about 15 C to about 35 C for a period of about 2 to about 20 days to provide a crude fermentation product containing red rice; drying said crude fermentation product to obtain red yeast rice, and then extracting said red yeast rice with a solvent -to provide an extract; and drying said extract to remove the solvent and produce red yeast rice extract.
The solvent is preferably either aqueous ethanol or just water. Other culture media may be added to the rice in the culturing step. For example, sugar, an additional carbon source, and one or more items chosen from the group consisting of glycerine, malt, and potato juice; thick beef juice, and defoamer.
The Red Yeast Rice extract is water soluble and is not soluble in the Omega-3 Oil. A
dispersant is preferably used to keep the Red Yeast Rice extract in suspension. One preferred dispersant is 70% silica bamboo with Lysine made from Sunflower oil.
A
suitable mixture is to vigorously mix 24 weights of Red Yeast Rice Extract with 36 weights of Fish Oil, 1.2 weights of Bamboo, and 1.8 weights of Lysine. The mixture may then diluted to the desired omega oil to red yeast rice extract ratio. The omega-3/red yeast rice extract is then preferably encapsulated in soft gelatin capsules.
Preferably the capsules are of such a size that an integral number of capsules comprise a daily dosage of the mixture.
- Bates. M. et al. Effectiveness of low dosage lovastatin in lowering serum cholesterol. Experience with 56 patients,õ Archives of Internal Medicine 1990:150(9) 8 Heber D. et al,_ Cholesterol Lowering effects of Proprietary Chinese red yeast rice dietary supplement, Am J Clin NuM 1999.69:231-236.
95112) Red Yeast Rice Extract 10:1, and the Thorne Research product, Choleast.
Purchased Red Yeast Rice preferably should contain 0.2% or more of Monacolin K
and 0.5% or more of Total Monacolins. We prefer to purchase the extract rather than manufacture it.
Red Yeast Rice Extract can also be manufactured directly from the yeast Monascus purpureus. The red yeast rice is the extract of fermenting- white rice, preferably non-glutinous white rice, with a Monascus purpureus strain of yeast, culturing said Monascus purpureus strain in a culture medium comprising rice at a temperature of about 15 C to about 35 C for a period of about 2 to about 20 days to provide a crude fermentation product containing red rice; drying said crude fermentation product to obtain red yeast rice, and then extracting said red yeast rice with a solvent -to provide an extract; and drying said extract to remove the solvent and produce red yeast rice extract.
The solvent is preferably either aqueous ethanol or just water. Other culture media may be added to the rice in the culturing step. For example, sugar, an additional carbon source, and one or more items chosen from the group consisting of glycerine, malt, and potato juice; thick beef juice, and defoamer.
The Red Yeast Rice extract is water soluble and is not soluble in the Omega-3 Oil. A
dispersant is preferably used to keep the Red Yeast Rice extract in suspension. One preferred dispersant is 70% silica bamboo with Lysine made from Sunflower oil.
A
suitable mixture is to vigorously mix 24 weights of Red Yeast Rice Extract with 36 weights of Fish Oil, 1.2 weights of Bamboo, and 1.8 weights of Lysine. The mixture may then diluted to the desired omega oil to red yeast rice extract ratio. The omega-3/red yeast rice extract is then preferably encapsulated in soft gelatin capsules.
Preferably the capsules are of such a size that an integral number of capsules comprise a daily dosage of the mixture.
7 A dosage of the mixture further preferably includes antioxidants an such as Rosemary, vitamin E, astaxanthine, carnitine, ascorbyl palmitate, tocopherols or other antioxidants known in the art for stabilizing fish oil.
It is preferred to use a high quality source of omega-3, which is rich in EPA
and DHA, preferably at least 70% Omega-3 Oils, which Omega-3 Oils are preferably 70%
EPA+DHA, and more preferably 85% or more EPA+DHA. A daily dose of Omega-3 oils is preferably 1 ¨ 4 grams of Omega -3. One possible source is a balanced Omega-formula such as Nordic Naturals, Inc. ProOmega which comprises 70% Omega-3 Oils which Omega-3 Oils are 50.8% EPA, 35.1% DHA and 14.1% other Omega-3.. Another preferred omega-3 source is Nordic Naturals Pro-EPA, whose Omega-3 comprise 69.1%
EPA, 16.3% DHA, and 14.6% other omega-3. Still another preferred source is Nordic Naturals Pro-EFA xtra which comprises 56.9% EPA, 14.7% DHA, 17.2% GLA, and 11.2% other Omega-3. The Pro-EFA xtra formula adds an Omega-6, GLA, and makes it a powerful anti-inflammatory mixture.
Examples One preferred embodiment is a daily dosage taken to reduce cholesterol and triglycerides comprising 1.2 grams per day of Red Yeast Rice Extract and 1700 mg of Nordic Naturals ProOmega (which contains 70% Omega-3 Oils which are 85.9% EPA+DHA, so that 1700 mg will supply 1000 mg/day of EPA=DHA). Here the ratio of fish oil to RYR
is 1700/1200= 1.4. To make the mixture add 1200 weights of Red Yeast Rice Extract to 1700 weights of fish oil. Add 58 weights (2%) of 70% silica bamboo and 87 weights (3%) of Lysine and mix thoroughly to make a stable suspension. Fill gelatin capsules with the mixture such that an integral number of capsules dispenses 3045 grams of mixture.
Another embodiment is a daily dose comprising 1.2 grams per day of Red Yeast Rice extract and 3400 mg of fish oil such as ProOmega. Here the ratio of fish oil to Red Yeast Rice is 2.8 and will supply 2000 mg/day of EPA+DHA.
It is preferred to use a high quality source of omega-3, which is rich in EPA
and DHA, preferably at least 70% Omega-3 Oils, which Omega-3 Oils are preferably 70%
EPA+DHA, and more preferably 85% or more EPA+DHA. A daily dose of Omega-3 oils is preferably 1 ¨ 4 grams of Omega -3. One possible source is a balanced Omega-formula such as Nordic Naturals, Inc. ProOmega which comprises 70% Omega-3 Oils which Omega-3 Oils are 50.8% EPA, 35.1% DHA and 14.1% other Omega-3.. Another preferred omega-3 source is Nordic Naturals Pro-EPA, whose Omega-3 comprise 69.1%
EPA, 16.3% DHA, and 14.6% other omega-3. Still another preferred source is Nordic Naturals Pro-EFA xtra which comprises 56.9% EPA, 14.7% DHA, 17.2% GLA, and 11.2% other Omega-3. The Pro-EFA xtra formula adds an Omega-6, GLA, and makes it a powerful anti-inflammatory mixture.
Examples One preferred embodiment is a daily dosage taken to reduce cholesterol and triglycerides comprising 1.2 grams per day of Red Yeast Rice Extract and 1700 mg of Nordic Naturals ProOmega (which contains 70% Omega-3 Oils which are 85.9% EPA+DHA, so that 1700 mg will supply 1000 mg/day of EPA=DHA). Here the ratio of fish oil to RYR
is 1700/1200= 1.4. To make the mixture add 1200 weights of Red Yeast Rice Extract to 1700 weights of fish oil. Add 58 weights (2%) of 70% silica bamboo and 87 weights (3%) of Lysine and mix thoroughly to make a stable suspension. Fill gelatin capsules with the mixture such that an integral number of capsules dispenses 3045 grams of mixture.
Another embodiment is a daily dose comprising 1.2 grams per day of Red Yeast Rice extract and 3400 mg of fish oil such as ProOmega. Here the ratio of fish oil to Red Yeast Rice is 2.8 and will supply 2000 mg/day of EPA+DHA.
8 Still another embodiment is a daily dose comprising 2.4 grams per day of Red Yeast Rice extract and 3400 mg of fish oil. Here the ratio of fish oil to Red Yeast Rice extract is 1.4.
Still another embodiment is a daily dose comprising 2.4 grams per day and 6800 mg of fish oil. Here the ratio of fish oil to Red Yeast Rice is 2.8.
Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Still another embodiment is a daily dose comprising 2.4 grams per day and 6800 mg of fish oil. Here the ratio of fish oil to Red Yeast Rice is 2.8.
Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
9
Claims (22)
1. A composition comprising (1) an omega-3 polyunsaturated fatty acid and (2) Red Yeast Rice, wherein component (1) is a mixture comprising at least 70 wt% of a combination of (A) eicosapentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA), wherein the weight ratio of A:B is 3:1 to 4:1, and wherein said Red Yeast Rice comprises at least 0.1 wt%
monacolin K.
monacolin K.
2. The composition of claim 1, wherein component (1) is derived from fish oil.
3. The composition of claim 1 or 2, wherein said Red Yeast Rice is dispersed in said omega-3 polyunsaturated fatty acid.
4. The composition of any one of claims 1 to 3, wherein said Red Yeast Rice comprises at least 0.2 wt% monacolin K and at least 0.4 wt% total monacolins.
5. The composition of any one of claims 2 to 4, wherein the fish oil comprises at least 60 wt% of Omega-3 oils.
6. The composition of claim 1, wherein component (1) comprises 50 wt% EPA
and 35 wt%
DHA.
and 35 wt%
DHA.
7. The composition of claim 1, wherein component (1) comprises 69 wt% EPA
and 16 wt%
DHA.
and 16 wt%
DHA.
8. The composition of claim 1, wherein the weight ratio of component (1) to component (2) is in the range of from 1.4 to 2.8.
9. The composition of any one of claims 1 to 8, further comprising a dispersing agent.
10. The composition of any one of claims 1 to 9, provided in a soft gelatin capsule.
11. The composition of any one of claims 1 to 10, wherein a daily dose of said composition comprises 1000 mg of the combination of (A) and (B) and 1200 mg of the Red Yeast Rice.
12. The composition of any one of claims 1 to 10, wherein the daily dose of the composition comprises 2000 mg of the combination of (A) and (B) and 1200 mg of the Red Yeast Rice.
13. The composition of any one of claims 1 to 10, wherein the daily dose of the composition comprises 2000 mg of the combination of (A) and (B) and 2400 mg of the Red Yeast Rice.
14. The composition of any one of claims 1 to 10, wherein the daily dose of the composition comprises 4000 mg of the combination of (A) and (B) and 2400 mg of the Red Yeast Rice.
15. The composition of any one of claims 1 to 10, further comprising an antioxidant.
16. The composition of claim 15, wherein the antioxidant is chosen from the group consisting of Rosemary, vitamin E, astaxanthine, carnitine, ascorbyl palmitate, and tocopherols.
17. Use of the composition according to any one of claims 1 to 9 for reducing serum cholesterol and triglycerides in a human.
18. The use as defined in claim 17, wherein said composition is provided in gelatin capsules.
19. The use as defined in claim 17 or 18, wherein said composition is used at a daily dosage providing 4000 mg of the combination of EPA plus DHA and 2400 mg of the Red Yeast Rice.
20. The use as defined in claim 17 or 18, wherein said composition is used at a daily dosage providing 1000 mg of the combination of EPA plus DHA and 1200 mg of the Red Yeast Rice.
21. The use as defined in claim 17 or 18, wherein said composition is used at a daily dosage providing 2000 mg of the combination of EPA plus DHA and 1200 mg of the Red Yeast Rice.
22. The use as defined in claim 17 or 18, wherein said composition is used at a daily dosage providing 2000 mg of the combination of EPA plus DHA and 2400 mg of the Red Yeast Rice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2676583A CA2676583C (en) | 2009-08-25 | 2009-08-25 | Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2676583A CA2676583C (en) | 2009-08-25 | 2009-08-25 | Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2676583A1 CA2676583A1 (en) | 2011-02-25 |
| CA2676583C true CA2676583C (en) | 2017-03-07 |
Family
ID=43618903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2676583A Active CA2676583C (en) | 2009-08-25 | 2009-08-25 | Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2676583C (en) |
-
2009
- 2009-08-25 CA CA2676583A patent/CA2676583C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2676583A1 (en) | 2011-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080299187A1 (en) | Substances for Reducing Occurence of Major Cardiac Events in Humans | |
| US11406602B2 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof | |
| CA2640414C (en) | Combinations of botanical extracts for promoting cardiovascular health | |
| RU2179440C2 (en) | Composition and method of inhibition of tumor cell and tumor growth with its using | |
| US11684600B2 (en) | Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort | |
| KR20080033410A (en) | Novel formulations comprising fenofibrate and a statin, and related methods of treatment | |
| US20120171285A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract | |
| AU2012211854A1 (en) | Prophylactic or therapeutic drug for peripheral neuropathy caused by anticancer agent | |
| US20120172425A1 (en) | Red yeast rice extract high in monacolin k content | |
| CA2676583C (en) | Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid | |
| US20210106541A1 (en) | Natural combination products and methods for regulation of total blood cholesterol | |
| WO2013138409A1 (en) | Red yeast rice extract high in monacolin k content | |
| WO2013138407A1 (en) | Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k | |
| BG2003U1 (en) | Remedy for prophylaxis and control of the level of total cholesterol | |
| RU2655803C2 (en) | Pharmaceutical composition for prevention and treatment of atherosclerosis | |
| RU2211043C2 (en) | Composition for preparing medicinal forms and enrichment of foodstuffs promoting to correction of disturbances in lipid metabolism, prophylaxis and treatment of atherosclerosis | |
| KR20140144433A (en) | Pharmaceutical composition for preventing or treating hyperlipidemia comprising fly maggot ethanol extracts | |
| FR2951908A1 (en) | COMPOSITION COMPRISING NOPAL POWDER AND RED RICE YEAST AND FOOD SUPPLEMENT COMPRISING THE SAME | |
| US20110319467A1 (en) | Absorption Enhancement of Statins and Omega Fatty Acids | |
| BG66783B1 (en) | Total cholesterol level prevention and regulation agent | |
| WO2013138411A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract | |
| IT201600075378A1 (en) | FOOD SUPPLEMENT BASED ON FERMENTED RED RICE | |
| Sterols | Emerging New Ingredients for Cardiovascular Health | |
| CN106456587A (en) | Solid formulations containing omega-3 and resveratrol | |
| CZ19730U1 (en) | Mixture of fatty acids and other biologically active compounds in the form of microemulsion for supporting dyslipidemia therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140822 |